Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus SUMYCIN.
AUREOMYCIN vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic